MiMedx To Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
MiMedx Group has announced that CEO Timothy R. Wright and CFO Peter M. Carlson will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference happening from December 1-3, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MiMedx Group has announced that CEO Timothy R. Wright and CFO Peter M. Carlson will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference happening from December 1-3, 2020. A pre-recorded presentation will be available on the company's website starting November 25, 2020, at 5:00 PM Eastern Time, and will be accessible for 45 days. MiMedx specializes in advanced wound care and therapeutic biologics, particularly using PURION technology to produce human placental tissue allografts, having supplied over 2 million allografts to date.
Details
News Market Reaction – MDXG
The recorded move for MDXG in the trading session of this news was +0.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MARIETTA, Ga., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1-3, 2020.
A pre-recorded presentation will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com beginning on November 25, 2020 at 5:00 PM Eastern Time and will be accessible for approximately 45 days.
About MiMedx
MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contact
Hilary Dixon
Investor Relations & Corporate Communications
770.651.9066
investorrelations@mimedx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.